Clinical trial NCT02651844 - References

Breast Cancer — Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B.

Citation(s)

•   Benagiano G, Bastianelli C, Farris M
  Selective progesterone receptor modulators 3: use in oncology, endocrinology and psychiatry. Expert Opin Pharmacother. 2008 Oct;9(14):2487-96. doi: 10.1517/14656566.9.14.2487 . Review.
•   Beral V; Million Women Study Collaborators
  Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003 Aug 9;362(9382):419-27. Erratum in: Lancet. 2003 Oct 4;362(9390):1160.
•   Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A; WHI Investigators
  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003 Jun 25;289(24):3243-53.
•   Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F
  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.
•   Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C; SEISMIC Study Investigators
  Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012 Jun;97(6):2039-49. doi: 10.1210/jc.2011-3350. Epub 2012 Mar 30.
•   Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel members
  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013 Sep;24(9):2206-23. doi: 10.1093/annonc/mdt303. Epub 2013 Aug 4.
•   Greiser CM, Greiser EM, Dören M
  Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials. Hum Reprod Update. 2005 Nov-Dec;11(6):561-73. Epub 2005 Sep 8.
•   Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC
  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010 Jun 1;28(16):2784-95. doi: 10.1200/JCO.2009.25.6529. Epub 2010 Apr 19. Review. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543.
•   Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ
  Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab. 1999 Dec;84(12):4559-65.
•   Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB
  The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol. 1997 Jun;11(6):693-705.
•   Jonat W, Bachelot T, Ruhstaller T, Kuss I, Reimann U, Robertson JFR
  Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Ann Oncol. 2013 Oct;24(10):2543-2548. doi: 10.1093/annonc/mdt216. Epub 2013 Jun 20.
•   Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P
  Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 1990 May;9(5):1603-14.
•   Klijn JG, Setyono-Han B, Foekens JA
  Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids. 2000 Oct-Nov;65(10-11):825-30. Review.
•   Lanari C, Wargon V, Rojas P, Molinolo AA
  Antiprogestins in breast cancer treatment: are we ready? Endocr Relat Cancer. 2012 May 3;19(3):R35-50. doi: 10.1530/ERC-11-0378. Print 2012 Jun. Review.
•   Lydon JP, Ge G, Kittrell FS, Medina D, O'Malley BW
  Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function. Cancer Res. 1999 Sep 1;59(17):4276-84.
•   Romieu G, Maudelonde T, Ulmann A, Pujol H, Grenier J, Cavalie G, Khalaf S, Rochefort H
  The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer. 1987;74(4):455-61.
•   Ulmann A, Dubois C
  Anti-progesterones in obstetrics, ectopic pregnancies and gynaecological malignancy. Baillieres Clin Obstet Gynaecol. 1988 Sep;2(3):631-8. Review.
•   Vanzulli S, Efeyan A, Benavides F, Helguero LA, Peters G, Shen J, Conti CJ, Lanari C, Molinolo A
  p21, p27 and p53 in estrogen and antiprogestin-induced tumor regression of experimental mouse mammary ductal carcinomas. Carcinogenesis. 2002 May;23(5):749-58.
•   Wargon V, Fernandez SV, Goin M, Giulianelli S, Russo J, Lanari C
  Hypermethylation of the progesterone receptor A in constitutive antiprogestin-resistant mouse mammary carcinomas. Breast Cancer Res Treat. 2011 Apr;126(2):319-32. doi: 10.1007/s10549-010-0908-x. Epub 2010 May 4.
•   Wargon V, Helguero LA, Bolado J, Rojas P, Novaro V, Molinolo A, Lanari C
  Reversal of antiprogestin resistance and progesterone receptor isoform ratio in acquired resistant mammary carcinomas. Breast Cancer Res Treat. 2009 Aug;116(3):449-60. doi: 10.1007/s10549-008-0150-y. Epub 2008 Aug 3.
•   Wargon V, Riggio M, Giulianelli S, Sequeira GR, Rojas P, May M, Polo ML, Gorostiaga MA, Jacobsen B, Molinolo A, Novaro V, Lanari C
  Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters. Int J Cancer. 2015 Jun 1;136(11):2680-92. doi: 10.1002/ijc.29304. Epub 2014 Nov 12.

Mifepristone Treatment for Breast Cancer Patients Expressing Levels of Progesterone Receptor Isoform A (PRA) Higher Than Those of Isoform B (PRB): Neoadjuvant Therapy.

Details for clinical trial NCT02651844